Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Segment Information

The following table sets forth the Company’s segment information (in thousands):

	Three Months Ended March 31,
	2026			2025
Direct external expenses by program:
Zidesamtinib	$	12,309		$	15,551
Neladalkib		26,316			28,007
NVL-330		6,826			3,961
Discovery programs		2,803			2,133
Personnel-related expenses		23,590			14,928
Stock-based compensation expense		28,880			20,380
General and administrative professional and consultant fees		4,343			2,866
Change in fair value of related party revenue share liability		2,570			1,430
Interest income		(12,862	)		(11,835	)
Other segment items(1)		14,336			7,004
Income tax provision		168			157
Consolidated net loss	$	(109,279	)	$	(84,582	)

(1) Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, employee recruitment, and other miscellaneous activities.